Sugi Predict

Sugi Predict / Compounds / SCHEMBL21132564

SCHEMBL21132564

SCHEMBL21132564

Cc1nc(Cl)c(C2OCCO2)c(Cl)n1

nearest known ligand 0.35

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ MEN1 O00255 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ KEAP1 Q14145 1/20 0.31
▸ NFE2L2 Q16236 1/20 0.31
▸ PDE10A Q9Y233 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28798823 0.92 MEN1 (0.33) NPC1RAB9AMEN1USP2MAPT
SCHEMBL25004287 0.90 NPC1 (0.33) NPC1RAB9A
SCHEMBL511479 0.82 NPC1 (0.33) NPC1RAB9A
SCHEMBL31148580 0.78 NPC1 (0.42) NPC1RAB9A
SCHEMBL31148642 0.78 KMT2A (0.35) NPC1RAB9AKMT2A
SCHEMBL28996428 0.78 — —
SCHEMBL28798786 0.75 TARBP2 (0.38) NPC1MAPTKMT2A
SCHEMBL28853648 0.75 — —
SCHEMBL29656516 0.75 TARBP2 (0.38) NPC1MAPTKMT2A
SCHEMBL28798885 0.75 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115057847-B Preparation method of 4, 6-dichloro-5- (1, 3-dioxolan-2-yl) -2-methylpyrimidine 山东百启生物医药有限公司 2024-01-26 — — CN claimed
CN-115057847-A Preparation method of 4, 6-dichloro-5- (1, 3-dioxolane-2-yl) -2-methylpyrimidine 山东百启生物医药有限公司 2022-09-16 — — CN claimed
EP-4615441-A1 COMPOUNDS AND COMPOSITIONS AS EIF4E INHIBITORS AND USES THEREOF Ribometrix, Inc. (US) 2025-09-17 — — EP disclosed
WO-2025000265-A1 HETEROCYCLIC COMPOUNDS USEFULL AS SOS1 INHIBITOR SILEXON AI TECHNOLOGY CO., LTD. (CN) 2025-01-02 — — WO disclosed
US-20240166645-A1 PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2024-05-23 — — US disclosed
WO-2024103067-A1 COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF RIBOMETRIX, INC. (US) 2024-05-16 — — WO disclosed
WO-2024103067-A1 COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF RIBOMETRIX, INC. (US) 2024-05-16 — — WO disclosed
US-20240051956-A1 SOS1 INHIBITORS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2024-02-15 — — US disclosed
CN-115057847-B Preparation method of 4, 6-dichloro-5- (1, 3-dioxolan-2-yl) -2-methylpyrimidine 山东百启生物医药有限公司 2024-01-26 — — CN disclosed
CN-115057847-B Preparation method of 4, 6-dichloro-5- (1, 3-dioxolan-2-yl) -2-methylpyrimidine 山东百启生物医药有限公司 2024-01-26 — — CN disclosed
CN-115057847-B Preparation method of 4, 6-dichloro-5- (1, 3-dioxolan-2-yl) -2-methylpyrimidine 山东百启生物医药有限公司 2024-01-26 — — CN disclosed
CN-114835703-A Substituted pyrimidopyridone inhibitor and preparation method and application thereof 苏州泽璟生物制药股份有限公司 2022-08-02 — — CN disclosed
WO-2022140427-A1 SOS1 INHIBITORS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2022-06-30 — — WO disclosed
WO-2022140427-A1 SOS1 INHIBITORS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2022-06-30 — — WO disclosed
CN-114539245-A Pyrimidine-fused ring derivative-containing regulator, and preparation method and application thereof 上海翰森生物医药科技有限公司 2022-05-27 — — CN disclosed
CN-114456165-A Nitrogen-containing fused ring derivative regulator, preparation method and application thereof 上海翰森生物医药科技有限公司 2022-05-10 — — CN disclosed
US-20210009588-A1 NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2021-01-14 — — US disclosed
WO-2020254451-A1 ANTICANCER COMBINATION THERAPY BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-12-24 — — WO disclosed
US-10829487-B2 Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-11-10 — — US disclosed
US-20190194192-A1 NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166645-A1 PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF SOS1, WEE1, SOS2 NPC1 2155/4885RAB9A 2595/4885MEN1 434/4885
US-20210009588-A1 NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS SOS1, SOST, SOS2 NPC1 1688/4885RAB9A 1210/4885MEN1 190/4885
US-20190194192-A1 NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS SOS1, SOST, SOS2 NPC1 1777/4885RAB9A 1209/4885MEN1 201/4885
US-10829487-B2 Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors SOS1, SOST, BMP1 NPC1 2054/4885RAB9A 1412/4885MEN1 115/4885
US-20240051956-A1 SOS1 INHIBITORS AND USES THEREOF SOS1, KRAS, NRAS NPC1 1405/4885RAB9A 56/4885MEN1 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.